An efficient and information-rich biochemical method design for fragment library screening on ion channels

BioTechniques

Volumn 49, Issue 5, 2010, Pages 822-829

  Thompson, Andrew J ^a   Verheij, Mark H P ^b   Leurs, Rob ^b   De Esch, Iwan J P ^b   Lummis, Sarah C R ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

5 HT3; Cys loop; Fragment; High throughput; Library; Ligand; Screen; Therapeutic

Indexed keywords

G PROTEIN COUPLED RECEPTOR; ION CHANNEL; LIGAND GATED ION CHANNEL; MEMBRANE PROTEIN; RADIOLIGAND; UNCLASSIFIED DRUG; VOLTAGE GATED ION CHANNEL;

ARTICLE; CHEMICAL ANALYSIS; CONTROLLED STUDY; HUMAN; HUMAN CELL; LIGAND BINDING; MAMMAL CELL; MOLECULAR LIBRARY; SCREENING;

CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; FLUORESCENT DYES; FLUOROMETRY; GENE EXPRESSION; GRANISETRON; HEK293 CELLS; HUMANS; LIGAND-GATED ION CHANNELS; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN; SEROTONIN ANTAGONISTS; TECHNOLOGY, PHARMACEUTICAL; TRANSFECTION; TRITIUM;

MAMMALIA;

EID: 78349241041     PISSN: 07366205     EISSN: None     Source Type: Journal    
DOI: 10.2144/000113538     Document Type: Article

References (26)

1. Hajduk, P.J. and J. Greer. 2007. A decade of fragment-based drug design: strategic advances and lessons learned. Nat. Rev. Drug Discov. 6:211-219.
2. Warr, W.A. 2009. Fragment-based drug discovery. J. Comput. Aided Mol. Des. 23:453-458.
3. Congreve, M., G. Chessari, D. Tisi, and A.J. Woodhead. 2008. Recent developments in fragment-based drug discovery. J. Med. Chem. 51:3661-3680.
4. de Kloe, G.E., D. Bailey, R. Leurs, and I.J. de Esch. 2009. Transforming fragments into candidates: small becomes big in medicinal chemistry. Drug Discov. Today 14:630-646.
5. Chen, I.-J. and R.E. Hubbard. 2009. Lessons for fragment library design: analysis of output from multiple screening campaigns. J. Comput. Aided Mol. Des. 23:603-620.
6. Hajduk, P.J. 2006. Fragment-based drug design: how big is too big? J. Med. Chem. 49:6972-6976.
7. Wood, W.J., A.W. Patterson, H. Tsuruoka, R.K. Jain, and J.A. Ellman. 2005. Substrate activity screening: a fragment-based method for the rapid identification of nonpeptidic protease inhibitors. J. Am. Chem. Soc. 127:15521-15527.
8. Shuker, S.B., P.J. Hajduk, R.P. Meadows, and S.W. Fesik. 1996. Discovering high-affinity ligands for proteins: SAR by NMR. Science 274:1531-1534.
9. Smits, R.A., H.D. Lim, A. Hanzer, O.P. Zuiderveld, E. Guaita, M. Adami, G. Coruzzi, R. Leurs, and I.J. de Esch. 2008. Fragment based design of new H4 receptor-ligands with anti-inflammatory properties in vivo. J. Med. Chem. 51:2457-2467.
10. Ulens, C., A. Akdemir, A. Jongejan, R. van Elk, S. Bertrand, A. Perrakis, R. Leurs, A.B. Smit, et al. 2009. Use of acetylcholine binding protein in the search for novel alpha7 nicotinic receptor ligands. in silico docking, pharmacological screening, and X-ray analysis. J. Med. Chem. 52:2372-2383.
11. Thompson, A.J. and S.C.R. Lummis. 2007. The 5-HT3 receptor as a therapeutic target. Expert Opin. Ther. Targets 11:527-540.
12. Webb, T.I. and J.W. Lynch. 2007. Molecular pharmacology of the glycine receptor chloride channel. Curr. Pharm. Des. 13:2350-2367.
13. Johnston, G.A. 2005. GABAA receptor channel pharmacology. Curr. Pharm. Des. 11:1867-1885.
14. Olsen, R.W. and W. Sieghart. 2009. GABAA receptors: subtypes provide diversity of function and pharmacology. Neuropharmacology 56:141-148.
15. Tang, W., J. Kang, X. Wu, D. Rampe, L. Wang, H. Shen, Z. Li, D. Dunnington, and T. Garyantes. 2001. Development and evaluation of high throughput functional assay methods for HERG potassium channel. J. Biomol. Screen. 6:325-331.
16. Shapiro, A.B., G.K. Walkup, and T.A. Keating. 2009. Correction for interference by test samples in high-throughput assays. J. Biomol. Screen. 14:1008-1016.
17. Leff, P. and I.G. Dougall. 1993. Further concerns over Cheng-Prusoff analysis. Trends Pharmacol. Sci. 14:110-112.
18. Cheng, Y. and W.H. Prusoff. 1973. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22:3099-3108.
19. Siegal, G., E. Ab, and J. Schultz. 2007. Integration of fragment screening and library design. Drug Discov. Today 12:1032-1039.
20. Xu, J. 2002. A new approach to finding natural chemical structure classes. J. Med. Chem. 45:5311-5320.
21. Hulme, E.C. and M.A. Trevethick. 2010. Ligand binding assays at equilibrium: validation and interpretation. Br. J. Pharmacol. Feb 2. [Epub ahead of print].
22. Gupta, A., A.K. Gupta, and K. Seshadri. 2009. Structural models in the assessment of protein druggability based on HTS data. J. Comput. Aided Mol. Des. 23:583-592.
23. Davies, D.R., B. Mamat, O.T. Magnusson, J. Christensen, M.H. Haraldsson, R. Mishra, B. Pease, E. Hansen, et al. 2009. Discovery of leukotriene A4 hydrolase inhibitors using metabolomics biased fragment crystallography. J. Med. Chem. 52:4694-4715.
24. Albert, J.S., N. Blomberg, A.L. Breeze, A.J. Brown, J.N. Burrows, P.D. Edwards, R.H. Folmer, S. Geschwindner, et al. 2007. An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from AstraZeneca's drug discovery programmes. Curr. Top. Med. Chem. 7:1600-1629.
25. Thompson, A.J. and S.C. Lummis. 2008. Antimalarial drugs inhibit human 5-HT3 and GABAA but not GABAC receptors. Br. J. Pharmacol. 153:1686-1696.
26. Brady, C.A., I.M. Stanford, I. Ali, L. Lin, J.M. Williams, A.E. Dubin, A.G. Hope, and N.M. Barnes. 2001. Pharmacological comparison of human homomeric 5-HT3A receptors versus heteromeric 5-HT3A/3B receptors. Neuropharmacology 41:282-284.